Pharmaceutical

Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease

SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with…

1 year ago

ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key Hires

LOS ANGELES, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), a leader in innovative wound care solutions,…

1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…

1 year ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8

DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to…

1 year ago

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

PITTSBURGH, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology…

1 year ago

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled…

1 year ago

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

1 year ago

23andMe Announces CEO’s Take-Private Proposal

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and…

1 year ago

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it…

1 year ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support…

1 year ago